Endoscopic retrograde cholangiopancreatography (ERCP) is an important diagnostic procedure to disclose the anatomy and nature of bile duct obstructions.1 2 In addition, decompression of the obstructed biliary system can be achieved by introduction of a nasobiliary suction catheter3 "4or a bile duct endoprosthesis.5 6 In 1979 prosthesis behind. This method was used in 13 patients.
In 12 patients, instead of the GIF IT, we used a specially constructed introducer, made from an old duodenoscope. Out of this duodenoscope the fibre bundles and the biopsy channel were removed and exchanged for a 3X8 mm instrumentation channel. This introducer was inserted over the balloon catheter and positioned in front of the papilla exactly like a duodenoscope for ERCP under constant fluoroscopic control. Through the instrumentation channel the endoprosthesis was pushed into position over the balloon catheter. In six patients a modified Fujinon duodenoscope was used. Along this duodenoscope a 4 mm internal diameter Teflon tube was loosely connected. At the tip of the endoscope the tube entered the duodenoscope where the biopsy channel ended. The same bridge was used to bend the cannulation catheter and the catheters leaving the outside instrumentation channel. In 14 patients a new Olympus prototype duodenoscope ( Fig. 2) with a 3-7 mm biopsy channel was used. With this endoscope it is possible to perform the ERCP, the papillotomy, and the introduction of the endoprosthesis in one procedure. After the papillotomy a 2 m long, 2-1 mm diameter catheter, carrying a 2-5 m long flexible guide wire was manoeuvred through the bile duct stenosis. Over the catheter the endoprosthesis was pushed into position. Alternatively, the long balloon catheter mentioned above can be used. Most patients were considered at high risk for any method of surgical treatment, because of age or concomitant diseases, such as cardiopulmonary insufficiency, diabetes, hypertension, and general debility. Furthermore, in 14 patients surgical treatment was considered impossible because of the localisation of the stenosis and the extent of malignancy in the right upper quadrant. In two patients a surgical bypass procedure had been unsuccessful. In three patients the percutaneous positioning of an endoprosthesis had failed. In one patient the endoprosthesis was inserted as a preoperative drainage procedure.
Results
In 45 patients a large bore endoprosthesis was successfully introduced. In three patients, early in our experience we were unable to push the endoprosthesis through the stenosis. In two patients the stenosis could not be passed by any type of catheter or guide wire. In four patients with an obstruction near the papilla it was impossible to perform a papillotomy and to pass the stenosis. In 34 patients the endoprosthesis was inserted immediately after the diagnostic ERCP. In 11 patients the first attempt to introduce an endoprosthesis failed, but a second attempt the next day was successful. In 43 patients a decline of the bilirubin level was observed. Itching, when present, disappeared within a few days in all patients. In two patients with multiple liver metastases, no decline of bilirubin levels was seen despite the endoscopically controlled patency of the endoprosthesis.
Bilirubin levels declined to normal or nearly normal levels in 25 patients after an average time interval of about one month (Table) . Eighteen patients died after a median time of 41 days (range three to 187 days). Four patients died the first week after insertion of the endoprosthesis because of liver insufficiency, despite declining bilirubin levels in two of them.
Nine patients died without jaundice. Five patients had recurrent jaundice shortly before death. In two of them necropsy was performed and a patent endoprosthesis with tumour growth above the endoprosthesis was found. In three of them necropsy was not allowed. One patient was treated with a surgical bypass 24 days after insertion of the endoprosthesis.
Twenty-six patients are still alive with a wellfunctioning endoprosthesis after a median time interval of 28 days (range seven to 244 days).
Complications
Fever and chills occurred in 11 patients the day after In two patients cholangitis developed respectively 34 and five months after insertion of the endoprosthesis. In both patients the endoprosthesis had moved upwards above the stenosis. In one patient the endoprosthesis could be pulled back into position. In the other patient a second endoprosthesis was inserted. At present we use an endoprosthesis with two barbs to prevent dislodgement in both directions. In one patient recurrent jaundice developed because of clogging of the endoprosthesis six months after insertion. The endoprosthesis was removed and a new one inserted. Five additional patients had recurrent jaundice shortly before death. In one patient a cholecystitis occurred six months after insertion of the endoprosthesis because of cystic duct occlusion. Cholecystectomy was performed, but she died from postoperative complications.
No patient needed a gastroenterostomy because of duodenal obstruction.
Discussion
Curative resections of malignancies causing obstructive jaundice can be attempted in only a small minority of patients. In most other patients only palliative bypass procedures are possible. The mortality of these surgical bypass procedures, however, is high, even up to 33%.9 Non-surgical methods to decompress the biliary system are percutaneous transhepatic drainage and percutaneous introduction of an endoprosthesis. This percutaneous approach has several disadvantages together with a considerable complication rate, mainly because a long, rather large, puncture channel through the liver tissue is made. A biliary fistula often remains, when the permanent positioning of a percutaneous prosthesis fails. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] It was logical to expect that an endoscopic technique should be developed for introduction of biliary endoprostheses through the natural orifice of the papilla and the natural common duct channel, thereby avoiding the main disadvantage of the percutaneous approach. Up to the present it has only been possible to introduce 2.1 mm diameter endoprostheses and, in our experience, these endoprostheses do not always guarantee an unimpeded bile flow. With the techniques described here, it is possible to introduce larger 3.2 mm diameter endoprostheses via the transpapillary route. The results obtained in 45 patients show that the biliary flow through such endoprostheses was adequate in all patients.
Cholangitis and chills shortly after insertion of the endoprosthesis occurred in 11 patients and could easily be managed conservatively. To avoid this complication, it is imperative to sterilise all ancillary equipment and to properly disinfect the endoscopes. For this purpose a special washing disinfecting machine was developed, capable of disinfecting also the minute channels supplying air and water within the endoscope.13 Using this machine no instance of iatrogenic infection within the bile duct has been observed. Therefore routine prophylactic antibiotics were omitted.
Late cholangitis occurred only in case of dislodgement or clogging of the endoprosthesis. Ascending cholangitis probably does not occur when the endoprosthesis is patent.
We prefer to position the endoprosthesis projecting from the papilla into the duodenum. This facilitates removal of the endoprosthesis if clogging occurs. When the lower end of the prosthesis is within the common duct it is nearly impossible to grasp and remove it. There is some fear that a transpapillary prosthesis may cause compression of the pancreatic orifice with subsequent pancreatitis. We have never observed pancreatitis in our patients. Whether this is explained by the routine papillotomy associated with the insertion of the prosthesis is uncertain at present, although this explanation seems to be plausible. No patients had complaints suggestive of injuries to the duodenal wall by the endoprosthesis because of pressure necrosis. Nor were injuries of the duodenal wall ever seen in those patients who had an endoscopy later on.
The endoscopic positioning of a biliary endoprosthesis has become a relatively easy procedure for experienced endoscopists since the introduction of a duodenoscope with a 3.7 mm biopsy channel. In two situations, however, the procedure remains very difficult or even impossible. In a very low bile duct stenosis it may be difficult to perform an adequate papillotomy, because proper introduction of the papillotome is prohibited. Tumours of the bifurcation can usually be passed with a flexible atraumatic guide wire entering both lobes of the liver. Introduction, however, of a catheter over this guidewire sometimes fails because the tumorous stenosis is too scirrhous to allow passage of the thicker Teflon catheter. Dilatation devices should be developed to overcome these difficulties, because optimal drainage is only achieved when a catheter can be positioned in both lobes of the liver. At present often only one lobe can be drained.
Many of the late complications related to biliary endoprostheses are due to clogging. Experiments are necessary to find out the most suitable material for the endoprostheses to avoid or retard this clogging phenomenon. At present it is not clear whether choleretic drugs or gallstone-dissolving agents are helpful in avoiding this clogging. The first experiences with endoscopically positioned 3.2 mm biliary endoprostheses are promising and suggest that this method may well become a great challenge to the percutaneous approach and possibly in the near future for the surgical bypass procedure as well. It is our conviction at present that the transpapillary approach should be the method of choice for all patients with malignant obstructive jaundice, who are at increased surgical risk. Whether this approach should be extended to all patients with malignant jaundice will only be known after properly controlled trials studying mortality, morbidity, survival time, and cost effectiveness together with the overall efficacy of drainage. 
